|
US5212071A
(en)
|
1988-04-01 |
1993-05-18 |
The Johns Hopkins University |
Nucleic acids encoding a human C3b/C4b receptor (CR1)
|
|
US5981481A
(en)
|
1974-12-06 |
1999-11-09 |
The Johns Hopkins University |
Human C3b/C4b receptor (CR1)
|
|
US4454151A
(en)
|
1982-03-22 |
1984-06-12 |
Syntex (U.S.A.) Inc. |
Use of pyrrolo pyrroles in treatment of ophthalmic diseases
|
|
US4943529A
(en)
|
1982-05-19 |
1990-07-24 |
Gist-Brocades Nv |
Kluyveromyces as a host strain
|
|
AU3145184A
(en)
|
1983-08-16 |
1985-02-21 |
Zymogenetics Inc. |
High expression of foreign genes in schizosaccharomyces pombe
|
|
US4879231A
(en)
|
1984-10-30 |
1989-11-07 |
Phillips Petroleum Company |
Transformation of yeasts of the genus pichia
|
|
US4797368A
(en)
|
1985-03-15 |
1989-01-10 |
The United States Of America As Represented By The Department Of Health And Human Services |
Adeno-associated virus as eukaryotic expression vector
|
|
US5139941A
(en)
|
1985-10-31 |
1992-08-18 |
University Of Florida Research Foundation, Inc. |
AAV transduction vectors
|
|
JPH0742235B2
(ja)
|
1985-11-08 |
1995-05-10 |
三共株式会社 |
自己免疫性疾病の予防・治療剤
|
|
GB8610600D0
(en)
|
1986-04-30 |
1986-06-04 |
Novo Industri As |
Transformation of trichoderma
|
|
US5260203A
(en)
|
1986-09-02 |
1993-11-09 |
Enzon, Inc. |
Single polypeptide chain binding molecules
|
|
US5733254A
(en)
|
1987-10-15 |
1998-03-31 |
Cypress Bioscience, Inc. |
Method for treating patients suffering from immune thrombocytopenic purpura
|
|
US5256642A
(en)
|
1988-04-01 |
1993-10-26 |
The Johns Hopkins University |
Compositions of soluble complement receptor 1 (CR1) and a thrombolytic agent, and the methods of use thereof
|
|
DE3830271A1
(de)
|
1988-09-06 |
1990-03-15 |
Goetze Otto |
Mittel mit immunsuppressiver wirkung
|
|
EP0397834B1
(en)
|
1988-10-28 |
2000-02-02 |
Genentech, Inc. |
Method for identifying active domains and amino acid residues in polypeptides and hormone variants
|
|
US5328470A
(en)
*
|
1989-03-31 |
1994-07-12 |
The Regents Of The University Of Michigan |
Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
|
|
ES2038579T3
(es)
|
1989-04-28 |
1997-02-16 |
Rhein Biotech Proz & Prod Gmbh |
Celulas de levadura del genero schwanniomyces.
|
|
EP0402226A1
(en)
|
1989-06-06 |
1990-12-12 |
Institut National De La Recherche Agronomique |
Transformation vectors for yeast yarrowia
|
|
FR2648133B1
(fr)
|
1989-06-08 |
1992-02-21 |
Sanofi Sa |
Lauramides n-substitues, leur preparation et compositions les contenant
|
|
FR2649120B1
(fr)
|
1989-06-30 |
1994-01-28 |
Cayla |
Nouvelle souche et ses mutants de champignons filamenteux, procede de production de proteines recombinantes a l'aide de ladite souche et souches et proteines obtenues selon ce procede
|
|
US5310729A
(en)
|
1990-04-20 |
1994-05-10 |
California Institute Of Biological Research |
Interferon-related polypeptides as CR2 ligands and their use for modulating immune cell functions
|
|
US5331090A
(en)
|
1989-09-08 |
1994-07-19 |
California Institute Of Biological Research |
CR2 ligand compositions and methods for modulating immune cell functions
|
|
US6458360B1
(en)
|
1990-04-25 |
2002-10-01 |
The Johns Hopkins University |
Soluble complement regulatory molecules
|
|
KR0185215B1
(ko)
|
1990-11-30 |
1999-05-01 |
요시다 쇼오지 |
서방성 안구삽입용 약제
|
|
EP1413587A2
(en)
|
1991-05-03 |
2004-04-28 |
Washington University |
Modified complement system regulator
|
|
US5178635A
(en)
|
1992-05-04 |
1993-01-12 |
Allergan, Inc. |
Method for determining amount of medication in an implantable device
|
|
DE4222534A1
(de)
|
1992-07-09 |
1994-01-13 |
Behringwerke Ag |
Verwendung von Komplement-Inhibitoren zur Herstellung eines Arzneimittels zur Prophylaxe und Therapie von entzündlichen Darm- und Hauterkrankungen sowie Purpura
|
|
US5679546A
(en)
|
1993-09-24 |
1997-10-21 |
Cytomed, Inc. |
Chimeric proteins which block complement activation
|
|
US6074642A
(en)
|
1994-05-02 |
2000-06-13 |
Alexion Pharmaceuticals, Inc. |
Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
|
|
US5679345A
(en)
|
1994-06-02 |
1997-10-21 |
The Johns Hopkins University |
Method for preventing complement-dependent rejection of organ or tissue transplants
|
|
JP3323508B2
(ja)
|
1994-10-25 |
2002-09-09 |
グラクソ グループ リミテッド |
Ｃｄ２３に対する結合物質
|
|
WO1997047321A1
(en)
|
1996-06-14 |
1997-12-18 |
The Johns Hopkins University School Of Medicine |
Use of chimeric vaccinia virus complement control proteins to inhibit complement
|
|
US5922320A
(en)
|
1996-06-14 |
1999-07-13 |
Georgetown University |
Recombinant proCVF
|
|
WO1998007835A2
(en)
|
1996-08-21 |
1998-02-26 |
Sugen, Inc. |
Crystal structures of a protein tyrosine kinase
|
|
US6214966B1
(en)
|
1996-09-26 |
2001-04-10 |
Shearwater Corporation |
Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
|
|
GB9624731D0
(en)
|
1996-11-28 |
1997-01-15 |
Univ Leicester |
Complement inhibitor
|
|
US6368596B1
(en)
|
1997-07-08 |
2002-04-09 |
Board Of Regents, The University Of Texas System |
Compositions and methods for homoconjugates of antibodies which induce growth arrest or apoptosis of tumor cells
|
|
US8088386B2
(en)
|
1998-03-20 |
2012-01-03 |
Genentech, Inc. |
Treatment of complement-associated disorders
|
|
WO1999037149A1
(en)
*
|
1998-01-27 |
1999-07-29 |
Brigham & Women's Hospital |
Methods of treating cytotoxic damage
|
|
JP4437192B2
(ja)
|
1998-02-20 |
2010-03-24 |
タノックス インコーポレイテッド |
補体活性化阻害剤
|
|
US7112327B2
(en)
|
1998-02-20 |
2006-09-26 |
Tanox, Inc. |
Inhibition of complement activation
|
|
AU3066699A
(en)
|
1998-03-03 |
1999-09-20 |
Johns Hopkins University, The |
Smallpox inhibitor of complement enzymes (spice) protein and methods of inhibiting complement activation
|
|
CA2331258C
(en)
*
|
1998-06-12 |
2011-09-20 |
Henry M. Jackson Foundation For The Advancement Of Military Medicine |
Enhancement of b cell activation and immunoglobulin secretion by co-stimulation of receptors for antigen and ebv gp350/220
|
|
US6572856B1
(en)
|
1998-09-10 |
2003-06-03 |
The University Of Virginia Patent Foundation |
Methods for the prevention and treatment of cancer using anti-C3b(i) antibodies
|
|
EP1001021B1
(en)
*
|
1998-09-25 |
2003-08-27 |
Wolfgang Prodinger |
Monoclonal antibody to human CD21, and its uses
|
|
US6224866B1
(en)
|
1998-10-07 |
2001-05-01 |
Biocrystal Ltd. |
Immunotherapy of B cell involvement in progression of solid, nonlymphoid tumors
|
|
AU776910B2
(en)
|
1998-12-08 |
2004-09-23 |
Merck Patent Gesellschaft Mit Beschrankter Haftung |
Modifying protein immunogenicity
|
|
CA2702148C
(en)
|
1999-01-06 |
2014-03-04 |
Genenews Inc. |
Method of profiling gene expression in a human subject having an infectious disease
|
|
US6943153B1
(en)
|
1999-03-15 |
2005-09-13 |
The Regents Of The University Of California |
Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
|
|
WO2000067796A1
(en)
|
1999-05-07 |
2000-11-16 |
Genentech, Inc. |
Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
|
|
US7576182B1
(en)
|
1999-08-31 |
2009-08-18 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
|
US6331313B1
(en)
|
1999-10-22 |
2001-12-18 |
Oculex Pharmaceticals, Inc. |
Controlled-release biocompatible ocular drug delivery implant devices and methods
|
|
GB0008582D0
(en)
|
2000-04-08 |
2000-05-31 |
Adprotech Plc |
DNA immunization vectors
|
|
JP4764590B2
(ja)
|
2000-04-29 |
2011-09-07 |
ユニバーシティー オブ アイオワ リサーチ ファウンデーション |
黄班変性関連疾患の診断および治療
|
|
US7439330B2
(en)
|
2000-05-08 |
2008-10-21 |
President And Fellows Of Harvard College |
Anti-glycated CD59 antibodies and uses thereof
|
|
JP2004508420A
(ja)
|
2000-09-18 |
2004-03-18 |
アイデック ファーマスーティカルズ コーポレイション |
Ｂ細胞枯渇抗体／免疫調節性抗体の組合せを用いて自己免疫疾患を治療するための併用療法
|
|
US7122181B2
(en)
|
2000-12-19 |
2006-10-17 |
Research Development Foundation |
Lentiviral vector-mediated gene transfer and uses thereof
|
|
AU2002255478A1
(en)
|
2001-01-10 |
2002-09-12 |
Pe Corporation (Ny) |
Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof
|
|
US7635680B2
(en)
|
2001-02-21 |
2009-12-22 |
Alavita Pharmaceuticals, Inc. |
Attenuation of reperfusion injury
|
|
US7645739B2
(en)
|
2001-02-21 |
2010-01-12 |
Alavita Pharmaceuticals, Inc. |
Modified annexin compositions and methods of using same
|
|
US7635676B2
(en)
|
2001-02-21 |
2009-12-22 |
Alavita Pharmaccuticals, Inc. |
Modified annexin proteins and methods for their use in organ transplantation
|
|
WO2002067857A2
(en)
|
2001-02-21 |
2002-09-06 |
Surromed, Inc. |
Modified annexin proteins and methods for preventing thrombosis
|
|
US6820011B2
(en)
*
|
2001-04-11 |
2004-11-16 |
The Regents Of The University Of Colorado |
Three-dimensional structure of complement receptor type 2 and uses thereof
|
|
JP2004529945A
(ja)
|
2001-05-17 |
2004-09-30 |
ラ ホヤ ファーマシューティカル カンパニー |
Ｃｄ２１を阻害する薬剤を使用して抗体媒介性病理を処置する方法
|
|
US20030181531A1
(en)
|
2003-02-11 |
2003-09-25 |
David Sherris |
Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases
|
|
AU2002336437A1
(en)
|
2001-08-29 |
2003-03-10 |
University Of Virginia Patent Foundation |
Therapeutic uses of complement receptor 2
|
|
AU2002346611A1
(en)
|
2001-12-03 |
2003-06-17 |
The Regents Of The University Of California |
Expression of glial-derived neurotrophic factor for treatment of diseases of the eye
|
|
EP1336618A1
(en)
|
2002-02-15 |
2003-08-20 |
HANS-KNÖLL-INSTITUT FÜR NATURSTOFF-FORSCHUNG e.V. |
Porcine complement regulator factor H and its use
|
|
US20030180292A1
(en)
|
2002-03-14 |
2003-09-25 |
Idec Pharmaceuticals |
Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy
|
|
AU2003218168A1
(en)
|
2002-03-15 |
2003-09-29 |
University Of Southern California |
Ophthalmic solutions for delivery of expression vectors
|
|
US20040058313A1
(en)
|
2002-04-24 |
2004-03-25 |
Abreu Marcio Marc |
Compositions, targets, methods and devices for the therapy of ocular and periocular disorders
|
|
AU2003298650B2
(en)
*
|
2002-11-15 |
2010-03-11 |
Musc Foundation For Research Development |
Complement receptor 2 targeted complement modulators
|
|
US7534427B2
(en)
|
2002-12-31 |
2009-05-19 |
Immunomedics, Inc. |
Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
|
|
AU2004224779A1
(en)
|
2003-03-28 |
2004-10-07 |
Laboratoires Serono Sa |
Use of clusterin for the treatment and/or prevention of peripheral neurological diseases
|
|
US20070123466A1
(en)
|
2003-05-13 |
2007-05-31 |
New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery |
Method of treating recurrent miscarriages
|
|
JP4029772B2
(ja)
|
2003-05-16 |
2008-01-09 |
株式会社日立製作所 |
磁気ヘッドおよびそれを用いた磁気記録再生装置
|
|
EP1488798A1
(en)
|
2003-06-18 |
2004-12-22 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
HIP/PAP polypeptide composition for use in liver regeneration and for the prevention of liver failure
|
|
WO2005014618A2
(en)
|
2003-08-08 |
2005-02-17 |
Immunomedics, Inc. |
Bispecific antibodies for inducing apoptosis of tumor and diseased cells
|
|
CN1878568A
(zh)
|
2003-11-05 |
2006-12-13 |
盘林京有限公司 |
Cdim结合抗体的增强的b细胞细胞毒性
|
|
US8454963B2
(en)
*
|
2003-11-13 |
2013-06-04 |
Musc Foundation For Research Development |
Tissue targeted complement modulators
|
|
US20050214286A1
(en)
|
2004-01-27 |
2005-09-29 |
University Of Southern California |
Polymer-bound antibody cancer therapeutic agent
|
|
BRPI0506629A
(pt)
|
2004-02-10 |
2007-05-02 |
Univ Colorado |
inibição do fator b, a via alternativa do sistema complemento e métodos relacionados
|
|
PL1713503T3
(pl)
|
2004-02-10 |
2014-02-28 |
Univ Colorado Regents |
Hamowanie czynnika B, alternatywny szlak dopełniacza i związane z tym sposoby
|
|
US7919094B2
(en)
|
2004-06-10 |
2011-04-05 |
Omeros Corporation |
Methods for treating conditions associated with MASP-2 dependent complement activation
|
|
JP5622351B2
(ja)
|
2004-09-03 |
2014-11-12 |
クレアビリス・セラピューティクス・エスピーエー |
プロテアーゼ抵抗性ヒトおよび非ヒトＨＭＧＢ１Ｂｏｘ−Ａ変異体、ならびにそれらの治療／診断への使用
|
|
US7563443B2
(en)
|
2004-09-17 |
2009-07-21 |
Domantis Limited |
Monovalent anti-CD40L antibody polypeptides and compositions thereof
|
|
US7423128B2
(en)
|
2004-11-03 |
2008-09-09 |
Amgen Fremont Inc. |
Anti-properdin antibodies, and methods for making and using same
|
|
JP2008520242A
(ja)
|
2004-11-18 |
2008-06-19 |
イェール ユニバーシティ |
視覚障害を処置するための方法および組成物
|
|
CA2593846A1
(en)
|
2005-01-14 |
2006-08-10 |
The Regents Of The University Of California |
Compositions and methods for inhibiting drusen formation and for diagnosing or treating drusen-related disorders
|
|
US7745389B2
(en)
*
|
2005-02-14 |
2010-06-29 |
University Of Iowa Research Foundation |
Methods for treatment of age-related macular degeneration
|
|
WO2006128006A1
(en)
|
2005-05-26 |
2006-11-30 |
The Regents Of The University Of Colorado |
Inhibition of the alternative complement pathway for treatment of traumatic brain injury, spinal cord injury and related conditions
|
|
GB2443370A
(en)
|
2005-07-29 |
2008-04-30 |
Australian Stem Cell Ct Ltd |
Compositions and methods for growth of pluripotent cells
|
|
US20090155381A1
(en)
|
2005-09-08 |
2009-06-18 |
Regina Goralczyc |
Method of treatment or prevention of age-related macular degeneration
|
|
US20070081989A1
(en)
|
2005-09-19 |
2007-04-12 |
Sanders Martin E |
Treatment of B cell diseases using anti-germline antibody binding agents
|
|
SG10201804008UA
(en)
|
2005-11-04 |
2018-06-28 |
Genentech Inc |
Use of complement pathway inhibitors to treat ocular diseases
|
|
US20110014270A1
(en)
|
2006-03-27 |
2011-01-20 |
The Regents Of The University Of Colorado |
Prevention and treatment of ischemia-reperfusion injury and related conditions
|
|
AR060487A1
(es)
|
2006-04-21 |
2008-06-18 |
Xoma Technology Ltd |
Composiciones farmaceuticas de antagonistas del anticuerpo anti- cd40
|
|
EP1854810A1
(en)
|
2006-05-09 |
2007-11-14 |
PanGenetics B.V. |
Deimmunized antagonistic anti-human CD40 monoclonal antibody from the ch5D12 antibody
|
|
US7759304B2
(en)
|
2006-06-21 |
2010-07-20 |
Regents Of The University Of Colorado |
Targeting complement factor H for treatment of diseases
|
|
US7705475B2
(en)
|
2006-08-03 |
2010-04-27 |
Stats Chippac Ltd. |
Integrated circuit package system
|
|
TW201716437A
(zh)
|
2006-11-02 |
2017-05-16 |
建南德克公司 |
人類化之抗-因子ｄ抗體及其用途
|
|
CN101668773B
(zh)
*
|
2007-03-14 |
2016-08-31 |
亚力史制药公司 |
人工程化抗b因子抗体
|
|
RU2473563C2
(ru)
|
2007-06-07 |
2013-01-27 |
Дженентек, Инк. |
АНТИТЕЛА ПРОТИВ C3b И СПОСОБЫ ПРОФИЛАКТИКИ И ЛЕЧЕНИЯ СВЯЗАННЫХ С КОМПЛЕМЕНТОМ НАРУШЕНИЙ
|
|
CN101970002B
(zh)
|
2007-08-27 |
2016-05-18 |
诺福麦德治疗学股份有限公司 |
用因子Bb特异性抗体抑制补体活化的方法
|
|
CL2008003241A1
(es)
|
2007-11-02 |
2009-07-31 |
Novartis Ag |
Molecula de enlace que comprende una porcion de enlace de antigeno que se enlaza con un neoepitopo de c3b; composicion farmaceutica que la comprende; y su uso para tratar trastornos oculares
|
|
DK2262831T3
(en)
|
2008-03-03 |
2015-04-27 |
Novelmed Therapeutics Inc |
ANTI-Properdin ANTIBODIES
|
|
PY09026846A
(es)
|
2008-08-05 |
2015-09-01 |
Novartis Ag |
Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5
|
|
JP5933975B2
(ja)
|
2008-11-12 |
2016-06-15 |
メディミューン，エルエルシー |
抗体製剤
|
|
US8840868B2
(en)
|
2009-02-04 |
2014-09-23 |
The Regents Of The University Of Colorado, A Body Corporate |
Non-invasive detection of complement-mediated inflammation using CR2-targeted nanoparticles
|
|
US20100291106A1
(en)
|
2009-05-06 |
2010-11-18 |
Novartis Ag |
Compositions and methods for antibodies targeting complement protein c3b
|
|
WO2010135717A2
(en)
|
2009-05-21 |
2010-11-25 |
Potentia Pharmaceuticals, Inc. |
Complement assays and uses thereof
|
|
WO2011003098A1
(en)
*
|
2009-07-02 |
2011-01-06 |
Musc Foundation For Research Development |
Methods of stimulating liver regeneration
|
|
CA2795311A1
(en)
|
2009-11-05 |
2011-05-12 |
Taligen Therapeutics, Inc. |
Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis
|
|
BR112012029067A2
(pt)
|
2010-05-14 |
2019-09-24 |
Univ Colorado Regents |
grupos-alvo de receptor do complemento 2 (cr2) melhorados.
|
|
SG186397A1
(en)
|
2010-06-22 |
2013-01-30 |
Univ Colorado Regents |
Antibodies to the c3d fragment of complement component 3
|
|
CN103248395A
(zh)
|
2012-02-09 |
2013-08-14 |
中兴通讯股份有限公司 |
一种窄带干扰抑制方法及装置
|
|
US9803005B2
(en)
|
2012-05-24 |
2017-10-31 |
Alexion Pharmaceuticals, Inc. |
Humaneered anti-factor B antibody
|